ZEO ScientifiX, a Leading South Florida Biotechnology Company, Launches Regenerative Medicine Educational Series for Physicians
ZEO ScientifiX (OTCQB:ZEOX), a South Florida-based clinical-stage biopharmaceutical company, has launched a monthly educational series for healthcare providers titled "The Future of Biologic Medicine: Expert-Led Discussions and Case Studies". These events offer insights into regenerative medicine, focusing on extracellular vesicles and autologous biologics, along with practical business solutions for integrating these therapies into medical practices.
The program includes expert-led discussions, tours of ZEO's cGMP-compliant laboratory at Nova Southeastern University, presentations on regulatory aspects, and networking opportunities. ZEO aims to help physicians leverage the clinical potential of biologic therapies and address real-world challenges in incorporating regenerative medicine into their practices.
ZEO recently completed successful Phase 1 clinical trials for its flagship product, Zofin™, and is seeking to launch Phase 2 trials for various indications. The company's goal is to obtain FDA approval for its products in treating various diseases and chronic conditions.
ZEO ScientifiX (OTCQB:ZEOX), un'azienda biofarmaceutica in fase clinica con sede nel sud della Florida, ha lanciato una serie di eventi educativi mensili per i fornitori di assistenza sanitaria intitolata "Il Futuro della Medicina Biologica: Discussioni e Studi di Caso Guidati da Esperti". Questi eventi offrono approfondimenti sulla medicina rigenerativa, concentrandosi su vescicole extracellulari e biologici autologhi, insieme a soluzioni pratiche per integrare queste terapie nelle pratiche mediche.
Il programma include discussioni guidate da esperti, visite al laboratorio conforme cGMP di ZEO presso la Nova Southeastern University, presentazioni sugli aspetti normativi e opportunità di networking. ZEO mira ad aiutare i medici a sfruttare il potenziale clinico delle terapie biologiche e affrontare le sfide reali nell'integrare la medicina rigenerativa nelle loro pratiche.
ZEO ha recentemente completato con successo la fase 1 degli studi clinici per il suo prodotto di punta, Zofin™, e sta cercando di lanciare la fase 2 per diverse indicazioni. L'obiettivo dell'azienda è ottenere l'approvazione della FDA per i suoi prodotti nel trattamento di varie malattie e condizioni croniche.
ZEO ScientifiX (OTCQB:ZEOX), una empresa biofarmacéutica en etapa clínica con sede en el sur de Florida, ha lanzado una serie de eventos educativos mensuales para proveedores de atención médica titulada "El Futuro de la Medicina Biológica: Discusiones y Estudios de Caso Guiados por Expertos". Estos eventos ofrecen información sobre medicina regenerativa, centrándose en vesículas extracelulares y biológicos autólogos, junto con soluciones comerciales prácticas para integrar estas terapias en las prácticas médicas.
El programa incluye discusiones lideradas por expertos, visitas al laboratorio conforme a cGMP de ZEO en la Universidad Nova Southeastern, presentaciones sobre aspectos regulatorios y oportunidades de networking. ZEO tiene como objetivo ayudar a los médicos a aprovechar el potencial clínico de las terapias biológicas y abordar los desafíos del mundo real en la incorporación de la medicina regenerativa en sus prácticas.
ZEO ha completado recientemente con éxito los ensayos clínicos de fase 1 para su producto insignia, Zofin™, y busca iniciar ensayos de fase 2 para diversas indicaciones. El objetivo de la empresa es obtener la aprobación de la FDA para sus productos en el tratamiento de diversas enfermedades y condiciones crónicas.
남부 플로리다에 본사를 둔 임상 단계의 생명공학 회사인 ZEO ScientifiX (OTCQB:ZEOX)는 "생물학적 의학의 미래: 전문가 주도 토론 및 사례 연구"라는 제목의 월간 교육 시리즈를 시작했습니다. 이 이벤트는 세포외 소포 및 자가생물학에 중점을 두고 재생 의학에 대한 통찰력을 제공하며, 이러한 치료법을 의료 관행에 통합하기 위한 실용적인 비즈니스 솔루션을 제공합니다.
프로그램에는 전문가 주도의 토론, 노바 사우스이스턴 대학교의 cGMP 준수 실험실 투어, 규제 측면에 대한 발표 및 네트워킹 기회가 포함됩니다. ZEO는 의사들이 생물학적 치료의 임상 잠재력을 활용하고 재생 의학을 그들의 관행에 통합하는데 있어 실제적인 도전에 대응하도록 돕는 것을 목표로 하고 있습니다.
ZEO는 최근 자사의 주력 제품인 Zofin™에 대한 성공적인 제1상 임상시험을 완료했으며, 다양한 적응증에 대해 제2상 시험을 시작할 계획입니다. 회사의 목표는 여러 질병 및 만성 질환 치료를 위한 제품에 대한 FDA 승인을 받는 것입니다.
ZEO ScientifiX (OTCQB:ZEOX), une entreprise biopharmaceutique en phase clinique basée en Floride du Sud, a lancé une série d'événements éducatifs mensuels pour les prestataires de soins de santé intitulée "L'avenir de la médecine biologique : Discussions dirigées par des experts et études de cas". Ces événements offrent des perspectives sur la médecine régénérative, en se concentrant sur les vésicules extracellulaires et les biologiques autologues, ainsi que sur des solutions commerciales pratiques pour intégrer ces thérapies dans les pratiques médicales.
Le programme comprend des discussions animées par des experts, des visites du laboratoire conforme aux cGMP de ZEO à l'Université Nova Southeastern, des présentations sur les aspects réglementaires et des opportunités de réseautage. ZEO vise à aider les médecins à tirer parti du potentiel clinique des thérapies biologiques et à relever les défis du monde réel pour intégrer la médecine régénérative dans leurs pratiques.
ZEO a récemment conclu avec succès des essais cliniques de phase 1 pour son produit phare, Zofin™, et cherche à lancer des essais de phase 2 pour diverses indications. L'objectif de l'entreprise est d'obtenir l'approbation de la FDA pour ses produits dans le traitement de diverses maladies et conditions chroniques.
ZEO ScientifiX (OTCQB:ZEOX), ein in Südflorida ansässiges biopharmazeutisches Unternehmen in der klinischen Phase, hat eine monatliche Bildungsreihe für Gesundheitsdienstleister ins Leben gerufen mit dem Titel "Die Zukunft der biologischen Medizin: Expertengeleitete Diskussionen und Fallstudien". Diese Veranstaltungen bieten Einblicke in die regenerative Medizin, wobei der Schwerpunkt auf extrazellulären Vesikeln und autologen Biologika liegt, sowie praktische Geschäftslösungen zur Integration dieser Therapien in medizinische Praxen.
Das Programm umfasst Expertengeleitete Diskussionen, Führungen durch das cGMP-konforme Labor von ZEO an der Nova Southeastern University, Präsentationen zu regulatorischen Aspekten und Networking-Möglichkeiten. ZEO hat das Ziel, Ärzten zu helfen, das klinische Potenzial biologischer Therapien zu nutzen und reale Herausforderungen bei der Integration regenerativer Medizin in ihre Praxen anzugehen.
ZEO hat kürzlich erfolgreich die Phase-1-Studien für sein Flaggschiffprodukt Zofin™ abgeschlossen und strebt an, Phase-2-Studien für verschiedene Indikationen zu starten. Das Ziel des Unternehmens ist es, die FDA-Zulassung für seine Produkte zur Behandlung verschiedener Krankheiten und chronischer Erkrankungen zu erhalten.
- Successful completion of Phase 1 clinical trials for flagship product Zofin™
- Planned launch of Phase 2 trials for multiple indications
- Establishment of educational series for healthcare providers, potentially increasing product awareness and adoption
- No FDA approval obtained yet for any products
- Still in clinical trial stages, indicating no immediate revenue from product sales
Events Hosted By ZEO ScientifiX Offer Providers Practical Business Tools Along With Science And Research Insights
FORT LAUDERDALE, FL / ACCESSWIRE / October 15, 2024 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a South Florida-based clinical-stage biopharmaceutical company, announced the launch of a monthly educational event for healthcare providers and members of their staff. The in-person events, titled "The Future of Biologic Medicine: Expert-Led Discussions and Case Studies," provide physicians the opportunity to learn about the science of regenerative medicine, with special emphasis on current research efforts surrounding the therapeutic potential of extracellular vesicles and innovative autologous biologics. In addition to clinical subject matter, ZEO's educational forums provide attendees with practical information, including the latest turnkey business solutions in practice by clinicians who have successfully integrated regenerative medicine products and services into their medical practices.
ZEO is one of the first clinical-stage biopharmaceutical companies to conduct this type of program in response to the growing demand from practitioners for information about biologic therapies and their availability to patients who may benefit. According to Precedence Research, the regenerative medicine space is expected to grow to a nearly
"ZEO's forums are an opportunity for us to bring doctors together who can learn the latest advancements in biologic medicine and can collaborate in real-time with their peers," said Jill Swartz, Chief Product Officer at ZEO. "We are committed to helping physicians leverage the clinical potential of these therapies in the patient care they deliver. We also understand the real-world challenges these providers face when it comes to incorporating regenerative medicine into their practices, so we're giving them practical business tools and resources they can access right away."
Each monthly event includes expert-led discussions facilitated by physicians and scientists on ZEO's research and development team; a tour of ZEO's state-of-the-art cGMP-compliant laboratory located at Nova Southeastern University, which is considered one of the top research collaboration complexes in the country; presentations about the regulatory environment surrounding regenerative medicine; and opportunities to network with like-minded healthcare providers. The Company held its first monthly event in early September and the second event on October 4, 2024. Its next forum is scheduled for Friday, November 8, at ZEO's corporate headquarters in Davie, Florida.
"For the providers who attend our educational forums, we're making tools available so they can leave here and, within days, implement what they have learned into their practices," Ms. Swartz said. "For doctors looking to explore the field of regenerative medicine and want to learn from trusted industry leaders, this is an essential opportunity."
ZEO recently completed successful Phase 1 clinical trials involving its flagship proprietary product, Zofin™. Now, the Company is actively seeking to launch Phase 2 trials for Zofin™ for several indications, along with other products in the Company's pipeline. ZEO's goal is to obtain FDA approval for the use of its products for the treatment of various diseases and chronic conditions.
For more information, or to schedule an interview, please contact Meieli Sawyer at msawyer@weinbachgroup.com or 305-668-0070.
About ZEO ScientifiX, Inc.
ZEO ScientifiX, Inc. (OTCQB:ZEOX) is a clinical-stage biopharmaceutical company located at Nova Southeastern University's Collaborative Center for Research. ZEO primarily focuses on the development of innovative biological therapeutics for the treatment of chronic diseases and the provision of related services. The Company's proprietary products are derived from allogenic and autologous sources and are manufactured in an FDA-registered, cGMP-compliant laboratory. To learn more, please visit https://zeoscientifix.com/.
Forward-Looking Statements
Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the "Securities Act"), the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995. These forward- looking statements are often identified by the use of forward-looking terminology such as "will," "believes," "expects," "potential," or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. No assurances can be given that the Company will be successful in its research initiatives. In addition, no assurances can be given that our research initiatives will increase the price of our common stock to a level that is attractive to brokerage houses and institutional investors. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations, including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including the risk factors discussed in the Company's periodic reports that are filed with the SEC and available on the SEC's website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. ZEO has no intention and specifically disclaims any duty to update the information in this press release.
Contact Information
Meieli Sawyer
Director of Communications
msawyer@weinbachgroup.com
305-668-0070
SOURCE: Zeo ScientifiX, Inc.
View the original press release on accesswire.com
FAQ
What is the focus of ZEO ScientifiX's (ZEOX) new educational series for physicians?
What stage of clinical trials has ZEO ScientifiX (ZEOX) reached with its product Zofin™?
Where are ZEO ScientifiX's (ZEOX) educational events held?
What is the projected growth rate of the regenerative medicine market according to the press release about ZEO ScientifiX (ZEOX)?
